← FDA DRUG APPROVALS

FDA ANDA · ANDA065271

AMOXICILLIN

Sponsor: AUROBINDO

APPLICATION
ANDA065271
TYPE
ANDA
ORIGINAL APPROVAL
2005-11-09
LATEST ACTION
2024-05-01
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

AMOXICILLINPrescription
AMOXICILLIN 500MG · CAPSULE · ORAL
AMOXICILLINPrescription
AMOXICILLIN 250MG · CAPSULE · ORAL

Approval history

2024-05-01Labeling · Supplement 25 · standardAP
2024-04-04Labeling · Supplement 19 · standardAP
2024-04-04Labeling · Supplement 23 · standardAP
2024-04-04Labeling · Supplement 15 · standardAP
2024-04-04Labeling · Supplement 16 · standardAP
2013-02-21Labeling · Supplement 9AP
2009-03-31Labeling · Supplement 5AP
2008-10-28Labeling · Supplement 4AP
2005-11-09OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →